An observational study in Epileptic Encephalopathy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 15 sites in France. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Assistance Publique Hopitaux De Marseille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille — 6 open to participants now, 7 under way, none of them phase 3. Epilepsy · Assistance Publique Hopitaux De Marseille.
Among the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, this one is one of 6 that started in 2021, is one of 3 observational ones, and was the 12th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →6 of the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18–90 · Healthy volunteers
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 9+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 16+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 12+
Assistance Publique Hopitaux De Marseille
Ages 18–18 · Healthy volunteers
By country, each count listing its studies:
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2021.
This study's planned enrollment of 200 is above the median of 107 across 541 observational studies indexed under Epilepsy.
Median enrollment 60 across the 15 interventional studies, 240 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
2 of the studies in Epilepsy by Assistance Publique Hopitaux De Marseille that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06334952Assistance Publique Hopitaux De MarseilleEfficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic | 2026-12-18 |
| NCT05609084Assistance Publique Hopitaux De MarseilleIntensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Electrical activity emerges in the third trimester of pregnancy, plays an important role in the construction of cortical maps, and is impaired in patients with severe early epileptic encephalopathies (EOEE). EOEE are rare and severe epileptic syndromes characterized by epilepsy that begins within the first three months of life and is associated with rapid deterioration of motor, cognitive and behavioral skills.
There is a genetic basis for the EOEE. Together with other laboratories, the investigators have identified de novo pathogenic variants in the KCNQ2 gene encoding the Kv7.2 subunit of the Kv7 / M potassium channel, a channel known to control neuronal excitability in the brain and spinal cord. via the current M (IM). Pathogenic variants of the KCNQ2 gene represent the main cause of EOEE and the term KCNQ2-related epileptic encephalopathy (KCNQ2-REE) is now used to define this condition.
KCNQ2-REE patients have a remarkably homogeneous phenotype at the start, with epilepsy that begins in the first days after birth, seizures that result in tonic muscle spasms that last from 1 to 10 seconds, and an interictal EEG called "suppression-burst". "That is, paroxysmal bursts of activity interspersed with periods of electrical silence. In this group, more than 50% of the patients present a remission of the epilepsy and a quasi-normalization of the EEG which can occur a few weeks to several months after the onset of the seizures. Despite this positive evolution in terms of seizures, the developmental progression is abnormal and the phenotype is severe with an absence of language, autistic behavior and a subsequent development of motor disorders such as diplegia, spasticity, ataxia or dystonia.
The ambition of this project is to increase knowledge of epileptic encephalopathies linked to KCNQ2 at the clinical and molecular levels, to decipher the pathophysiological mechanisms and to propose therapeutic strategies.
This project aims to better describe the clinical, EEG, imaging, developmental and long-term follow-up characteristics of patients carrying the KCNQ2 mutation identified in the laboratory.
Retrospective observational study initially then prospective with inclusion of all patients with a KCNQ2-REE whose diagnosis was made in the EPIGENE network
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
directive questionnaire administered during an individual face-to-face interview
importance of the developmental disorder
Developmental quotient
Time frame: Month 36
definition of the active phase of epilepsy
Presence of at least monthly seizures and interictal EEG showing paroxysmal abnormalities
Time frame: Month 36
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Sep 2029, 102 months after the start.
Of 193 non-industry observational studies under Epilepsy, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 179. This study's planned 102 months is above that.
Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 24 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →